Log in

Relevant bibliographies by topics / Molecular Targeted Therapy / Journal articles

To see the other types of publications on this topic, follow the link: Molecular Targeted Therapy.

Journal articles on the topic 'Molecular Targeted Therapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Molecular Targeted Therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Eto, Masatoshi. "PD2-5 The Role of Cytokine Therapy at the Age of Molecular Targeted Therapy." Japanese Journal of Urology 99, no. 2 (2008): 134. http://dx.doi.org/10.5980/jpnjurol.99.134_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dong, Bing, and Yi-Min Zhu. "Molecular-targeted therapy for cancer." Chinese Journal of Cancer 29, no. 3 (March 5, 2010): 340–45. http://dx.doi.org/10.5732/cjc.009.10313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Park, Hee-Sook, and Nam-Su Lee. "Molecular Targeted Therapy in Cancer." Journal of the Korean Medical Association 46, no. 6 (2003): 542. http://dx.doi.org/10.5124/jkma.2003.46.6.542.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Festuccia, Claudio, Assunta Leda Biordi, Vincenzo Tombolini, Akira Hara, and David Bailey. "Targeted Molecular Therapy in Glioblastoma." Journal of Oncology 2020 (January 14, 2020): 1–3. http://dx.doi.org/10.1155/2020/5104876.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gala, Kinisha, and Sarat Chandarlapaty. "Molecular Pathways: HER3 Targeted Therapy." Clinical Cancer Research 20, no. 6 (February 11, 2014): 1410–16. http://dx.doi.org/10.1158/1078-0432.ccr-13-1549.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Puzanov, Igor, and Keith T. Flaherty. "Targeted Molecular Therapy in Melanoma." Seminars in Cutaneous Medicine and Surgery 29, no. 3 (September 2010): 196–201. http://dx.doi.org/10.1016/j.sder.2010.06.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Le Rhun, Emilie, Matthias Preusser, Patrick Roth, David A. Reardon, Martin van den Bent, Patrick Wen, Guido Reifenberger, and Michael Weller. "Molecular targeted therapy of glioblastoma." Cancer Treatment Reviews 80 (November 2019): 101896. http://dx.doi.org/10.1016/j.ctrv.2019.101896.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Mischel, Paul S., and Timothy F. Cloughesy. "Targeted Molecular Therapy of GBM." Brain Pathology 13, no. 1 (April 5, 2006): 52–61. http://dx.doi.org/10.1111/j.1750-3639.2003.tb00006.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Stadler, Walter. "IL-6 (S) Progress in Molecular Targeted Therapy for Renal Cell Cancer." Japanese Journal of Urology 98, no. 2 (2007): 59. http://dx.doi.org/10.5980/jpnjurol.98.59.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Karczmarek-Borowska, Bożenna, and Agata Sałek-Zań. "Review Hepatotoxicity of molecular targeted therapy." Współczesna Onkologia 2 (2015): 87–92. http://dx.doi.org/10.5114/wo.2014.43495.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Terry, Kimberly, and Mehmet Sitki Copur. "Molecular Targeted Therapy of Hepatocellular Carcinoma." Journal of Cancer Therapy 04, no. 02 (2013): 426–39. http://dx.doi.org/10.4236/jct.2013.42a052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Kimura, Teruaki, and Mitsuru Adachi. "Molecular Targeted Therapy for Refractory Asthma." Nihon Naika Gakkai Zasshi 98, no. 12 (2009): 3154–59. http://dx.doi.org/10.2169/naika.98.3154.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ahn, Myung-Ju. "Molecular Targeted Therapy in Lung Cancer." Hanyang Medical Reviews 34, no. 1 (2014): 37. http://dx.doi.org/10.7599/hmr.2014.34.1.37.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Kishimoto, Mitsumasa, Yoshinori Komagata, and Shinya Kaname. "III. Molecular Targeted Therapy in Spondyloarthritis." Nihon Naika Gakkai Zasshi 110, no. 10 (October 10, 2021): 2173–80. http://dx.doi.org/10.2169/naika.110.2173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Suzuki, Shigeaki. "Targeted molecular therapy for myasthenia gravis." Lancet Neurology 20, no. 7 (July 2021): 499–500. http://dx.doi.org/10.1016/s1474-4422(21)00173-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Kalachand, Roshni, Bryan T. Hennessy, and Maurie Markman. "Molecular Targeted Therapy in Ovarian Cancer." Drugs 71, no. 8 (May 2011): 947–67. http://dx.doi.org/10.2165/11591740-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Ito, Yoshinori. "Molecular targeted therapy for breast cancer." Breast Cancer 14, no. 2 (April 2007): 131. http://dx.doi.org/10.2325/jbcs.974.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Heo, Dae Seog. "Molecular Targeted Therapy for Lung Cancer." Journal of the Korean Medical Association 46, no. 1 (2003): 46. http://dx.doi.org/10.5124/jkma.2003.46.1.46.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Sullivan, Ryan J., and Michael B. Atkins. "Molecular-targeted therapy in malignant melanoma." Expert Review of Anticancer Therapy 9, no. 5 (May 2009): 567–81. http://dx.doi.org/10.1586/era.09.20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Sobue, Gen. "Molecular-targeted therapy for neurodegenerative diseases." Rinsho Shinkeigaku 49, no. 11 (2009): 747–49. http://dx.doi.org/10.5692/clinicalneurol.49.747.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

O'ROURKE, DONALD M. "Targeted Molecular Therapy In Glial Tumors." Neurosurgery 54, no. 5 (May 2004): N9. http://dx.doi.org/10.1227/01.neu.0000309633.00854.fd.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Tada, Yuji, Toshio Suzuki, Hideaki Shimada, Kenzo Hiroshima, Koichiro Tatsumi, and Masatoshi Tagawa. "Molecular-Targeted Therapy For Malignant Mesothelioma." PLEURA 2 (August 17, 2015): 237399751560040. http://dx.doi.org/10.1177/2373997515600403.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Tian, Lei. "Molecular targeted therapy of gastric cancer." World Chinese Journal of Digestology 22, no. 6 (2014): 773. http://dx.doi.org/10.11569/wcjd.v22.i6.773.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Wang, Qiao-Feng. "Molecular targeted therapy in gastric cancer." World Chinese Journal of Digestology 23, no. 31 (2015): 4982. http://dx.doi.org/10.11569/wcjd.v23.i31.4982.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Sheikh, MS. "Spotlight on molecular targeted therapy: introduction." Leukemia 16, no. 4 (April 2002): 431–32. http://dx.doi.org/10.1038/sj.leu.2402418.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Nishimura, Satoru. "Molecular targeted therapy of breast cancer." Tenri Medical Bulletin 18, no. 2 (2015): 65–69. http://dx.doi.org/10.12936/tenrikiyo.18-008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hashimoto, Seisyu. "Molecular targeted therapy of lung cancer." Tenri Medical Bulletin 18, no. 2 (2015): 75–79. http://dx.doi.org/10.12936/tenrikiyo.18-009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Chaudhry, Nauman S., Wenya Linda Bi, Saksham Gupta, Abhishek Keraliya, Naomi Shimizu, and E. Antonio Chiocca. "Pneumatosis Intestinalis After Molecular-Targeted Therapy." World Neurosurgery 125 (May 2019): 312–15. http://dx.doi.org/10.1016/j.wneu.2019.01.225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Onn, Amir, and Roy S. Herbst. "Molecular targeted therapy for lung cancer." Lancet 366, no. 9496 (October 2005): 1507–8. http://dx.doi.org/10.1016/s0140-6736(05)67608-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Trueman, P. "Pharmacoeconomic challenges of molecular targeted therapy." European Journal of Cancer Supplements 5, no. 9 (December 2007): 2–3. http://dx.doi.org/10.1016/j.ejcsup.2007.09.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Thomas, Melanie. "Molecular targeted therapy for hepatocellular carcinoma." Journal of Gastroenterology 44, S19 (January 2009): 136–41. http://dx.doi.org/10.1007/s00535-008-2252-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Seike, Masahiro. "Molecular Targeted Therapy of Lung Cancer." Nihon Ika Daigaku Igakkai Zasshi 14, no. 4 (October 15, 2018): 177–79. http://dx.doi.org/10.1272/manms.14.177.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Nabors, L. Burt. "Targeted molecular therapy for malignant gliomas." Current Treatment Options in Oncology 5, no. 6 (December 2004): 519–26. http://dx.doi.org/10.1007/s11864-004-0040-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kesari, Santosh, Naren Ramakrishna, Claire Sauvageot, Charles D. Stiles, and Patrick Y. Wen. "Targeted molecular therapy of malignant gliomas." Current Neurology and Neuroscience Reports 5, no. 3 (May 2005): 186–97. http://dx.doi.org/10.1007/s11910-005-0046-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Kesari, Santosh, Naren Ramakrishna, Claire Sauvageot, Charles D. Stiles, and Patrick Y. Wen. "Targeted molecular therapy of malignant gliomas." Current Oncology Reports 8, no. 1 (January 2006): 58–70. http://dx.doi.org/10.1007/s11912-006-0011-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Yu, Su Jong, and Jung-Hwan Yoon. "Molecular targeted therapy with transarterial chemoembolization." Gastrointestinal Intervention 2, no. 2 (December 2013): 78–81. http://dx.doi.org/10.1016/j.gii.2013.09.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Yao, James C., and Paulo M. Hoff. "Molecular Targeted Therapy for Neuroendocrine Tumors." Hematology/Oncology Clinics of North America 21, no. 3 (June 2007): 575–81. http://dx.doi.org/10.1016/j.hoc.2007.04.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Xiang, Miao, and Ximing Xu. "Molecular targeted therapy in gastrointestinal cancer." Chinese-German Journal of Clinical Oncology 10, no. 7 (July 2011): 380–85. http://dx.doi.org/10.1007/s10330-011-0797-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Xu, Miao, Jianyong Shao, and Yixin Zeng. "Molecular classification and molecular targeted therapy of cancer." Frontiers of Medicine 7, no. 2 (May 20, 2013): 147–49. http://dx.doi.org/10.1007/s11684-013-0274-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Denu, Ryan A., Amanda M. Dann, Emily Z. Keung, Michael S. Nakazawa, and Elise F. Nassif Haddad. "The Future of Targeted Therapy for Leiomyosarcoma." Cancers 16, no. 5 (February 26, 2024): 938. http://dx.doi.org/10.3390/cancers16050938.

Full text

Abstract:

Leiomyosarcoma (LMS) is an aggressive subtype of soft tissue sarcoma that arises from smooth muscle cells, most commonly in the uterus and retroperitoneum. LMS is a heterogeneous disease with diverse clinical and molecular characteristics that have yet to be fully understood. Molecular profiling has uncovered possible targets amenable to treatment, though this has yet to translate into approved targeted therapies in LMS. This review will explore historic and recent findings from molecular profiling, highlight promising avenues of current investigation, and suggest possible future strategies to move toward the goal of molecularly matched treatment of LMS. We focus on targeting the DNA damage response, the macrophage-rich micro-environment, the PI3K/mTOR pathway, epigenetic regulators, and telomere biology.

APA, Harvard, Vancouver, ISO, and other styles

41

Wilkes, GailM. "Targeted Therapy: Attacking Cancer with Molecular and Immunological Targeted Agents." Asia-Pacific Journal of Oncology Nursing 5, no. 2 (2018): 137. http://dx.doi.org/10.4103/apjon.apjon_79_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

WANG, Zai-biao, and Li-ye MA. "Molecular targeted therapy of gastric cancer：recent progress." Academic Journal of Second Military Medical University 35, no. 3 (2014): 305. http://dx.doi.org/10.3724/sp.j.1008.2014.00305.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Roychoudhury, Sayantani, Ajay Kumar, Devyani Bhatkar, and Nilesh Kumar Sharma. "Molecular avenues in targeted doxorubicin cancer therapy." Future Oncology 16, no. 11 (April 2020): 687–700. http://dx.doi.org/10.2217/fon-2019-0458.

Full text

Abstract:

In recent, intra- and inter-tumor heterogeneity is seen as one of key factors behind success and failure of chemotherapy. Incessant use of doxorubicin (DOX) drug is associated with numerous post-treatment debacles including cardiomyopathy, health disorders, reversal of tumor and formation of secondary tumors. The module of cancer treatment has undergone evolutionary changes by achieving crucial understanding on molecular, genetic, epigenetic and environmental adaptations by cancer cells. Therefore, there is a paradigm shift in cancer therapeutic by employing amalgam of peptide mimetic, small RNA mimetic, DNA repair protein inhibitors, signaling inhibitors and epigenetic modulators to achieve targeted and personalized DOX therapy. This review summarizes on recent therapeutic avenues that can potentiate DOX effects by removing discernible pitfalls among cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

44

Saeki, Kyosuke, Yoshinobu Maeda, and Mitsune Tanimoto. "Molecular targeted therapy in myeloma and lymphoma." Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 126, no. 2 (2014): 143–50. http://dx.doi.org/10.4044/joma.126.143.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Karale, Pushpa A., Mahesh A. Karale, and Mokshada C. Utikar. "Advanced Molecular Targeted Therapy in Breast Cancer." Research Journal of Pharmacology and Pharmacodynamics 10, no. 1 (2018): 29. http://dx.doi.org/10.5958/2321-5836.2018.00006.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Reichardt, P., A. Reichardt, and D. Pink. "Molecular Targeted Therapy of Gastrointestinal Stromal Tumors." Current Cancer Drug Targets 11, no. 6 (July 1, 2011): 688–97. http://dx.doi.org/10.2174/156800911796191042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Wickline, Samuel A., and Gregory M. Lanza. "Nanotechnology for Molecular Imaging and Targeted Therapy." Circulation 107, no. 8 (March 4, 2003): 1092–95. http://dx.doi.org/10.1161/01.cir.0000059651.17045.77.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Daver, Naval, and Jorge Cortes. "Molecular targeted therapy in acute myeloid leukemia." Hematology 17, sup1 (April 1, 2012): s59—s62. http://dx.doi.org/10.1179/102453312x13336169155619.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Almeida, A. M., Y. Murakami, A. Baker, Y. Maeda, Irene Roberts, Taroh Kinoshita, D. M. Layton, and A. Karadimitris. "Targeted Molecular Therapy for Inherited Glycosylphosphatidylinositol Deficiency." Blood 108, no. 11 (November 16, 2006): 487. http://dx.doi.org/10.1182/blood.v108.11.487.487.

Full text

Abstract:

Abstract Inherited glycosylphosphatidylinositol (GPI) deficiency (IGD) is an autosomal recessive disease characterized by splanchnic vein thrombosis and epilepsy. The partial GPI deficiency in the affected children is due to disrupted addition of the first mannose residue onto the GPI intermediate PI-GlcN, a step catalyzed by the α1>4 mannosyltranferase PIGM. IGD is caused by a −270C>G substitution in the core promoter of PIGM which disrupts binding of the transcription factor (TF) Sp1 to its cognate motif resulting in markedly reduced transcription. Sp1 regulates transcription through interactions an with the basal transcriptional complex or with other TF. In some genes, Sp1 is also required for locus histone acetylation. We investigated whether histone acetylation of the PIGM locus was Sp1-dependent and whether histone deacetylase (HDAC) inhibitors such as sodium butyrate (SB) could be used to enhance PIGM transcription even in the presence of the mutated Sp1 binding motif associated with IGD. Using ChIP assays we first showed that histone 4 (H4) at the PIGM locus is constitutively acetylated in GPI+ EBV B cell lines (LBCL), consistent with the housekeeping function of PIGM. By contrast, the same H4 in GPI- LBCL from individuals with IGD was hypoacetylated indicating that efficient PIGM promoter acetylation requires an intact Sp1 core promoter motif. Upon exposure to SB, acetylation was completely restored in the affected cell lines. Consistent with this, in luciferase reporter assays performed in the presence of mithramycin, an agent that specifically inhibits Sp binding, the enhancing effect of SB on transcription driven by both wild type and mutant (−270C>G) promoter constructs was largely (but not exclusively) Sp1-dependent. The increased transcriptional activity of the mutated PIGM promoter in the presence of SB was accompanied by a more than 100-fold increase in the PIGM mRNA and almost complete restoration of surface GPI expression in the affected LBCL. Over a period of 10 years, one of the children with IGD developed progressive, intractable and incapacitating seizures, despite a multitude of different anti-epileptic treatments including sodium valproate. At the age of 14, she was wheelchair-bound with global hypotonia, extreme drowsiness, poorly responsive, unable to feed herself and almost permanently in minor status with approximately 5 tonic-clonic seizures/day. Extensive CNS imaging showed no structural abnormalities or evidence of thrombosis. An EEG was consistent with minor status epilepticus. Guided by the effectiveness of SB in restoring PIGM transcription and GPI expression in vitro, the patient was commenced on sodium phenylbutyrate (SPB) at an oral dose of 20mg/kg tds. SPB treatment induced a progressive increase in the proportions of GPI+ granulocytes and an increase in PIGM mRNA levels in primary mononuclear blood cells from a pre-SPB level of 1.65% to 26%. A marked clinical improvement was noted after only 2 weeks of treatment, in that the patient could walk, interact with others and feed herself and became entirely seizure-free; she remains so 6 months later. No side effects were noted. These data suggest that SPB may be an effective therapeutic option for diseases caused by Sp1-dependent histone hypoacetylation and also for diseases caused by non-inactivating mutations in the coding region of genes where transcription is regulated by Sp1-dependent histone acetylation.

APA, Harvard, Vancouver, ISO, and other styles

50

Wu, Qing, and Zhao-Shen Li. "Molecular targeted therapy of digestive system neoplasms." World Chinese Journal of Digestology 16, no. 32 (2008): 3666. http://dx.doi.org/10.11569/wcjd.v16.i32.3666.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!